AS

Anjali Shukla

Active Director Director DIN 09723338
DIN 09723338 First appointment Aug 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2022
Shareholding value •••• Premium profile

About Anjali Shukla

Data last updated:

Anjali Shukla is a Director at Celiom Newtraceuticals Private Limited (since 2022). The company operates in Chemicals. Celiom Newtraceuticals Private Limited reported revenue of ₹5,000 (FY 2025).

DIN 09723338
Primary Designation Director
Industry Chemicals
First Appointment 31 Aug 2022
Oldest Company Age 4 yrs
Largest company Celiom Newtraceuticals Private Limited · ₹5,000 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director31 Aug 20222022₹5,000 (FY 2025)Active

Board colleagues of Anjali Shukla

NameDINCompanyDesignation
Shreya Khanna09723337Celiom Newtraceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Celiom Newtraceuticals Private Limited
Premium access

Shareholding and investment profile for Anjali Shukla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anjali Shukla

Anjali Shukla currently holds 1 directorship: Celiom Newtraceuticals Private Limited (Director, since 31 Aug 2022, revenue ₹5,000 (FY 2025)).

Anjali Shukla was first appointed on 31 Aug 2022 as Director at Celiom Newtraceuticals Private Limited.

The current boards of Anjali Shukla's companies include Shreya Khanna (Celiom Newtraceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available